Our group has also recently shown the presence of immunoreactive human chymase in DVT derived from patients and have also reported that recombinant CMA-1 inactivates purified human plasmin’s hydrolytic properties in a chymase inhibitor-sensitive manner (15). Here, CMA1 is linked to deep vein thrombosis.